证券代码：301393 证券简称：昊帆生物 公告编号：2025-055 苏州昊帆生物股份有限公司 第四届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 苏州昊帆生物股份有限公司（以下简称"公司"）第四届董事会第十四次会 议于 2025 年 11 月 21 日在公司会议室以现场方式召开，会议通知于 2025 年 11 月 19 日以专人送达及电话等方式发出。 本次会议由董事长朱勇先生主持，会议应出席董事 9 人，实际出席 9 人。公 司全体监事、高级管理人员列席本次会议。本次会议的召集、召开符合《公司法》 和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事以记名投票表决方式，审议并通过了如下议案： （一）审议并通过《关于修订<公司章程>的议案》 公司根据《公司法》《上市公司章程指引》等相关法律、法规及规范性文件 的规定，为进一步完善公司治理制度，结合公司实际情况，公司拟调整治理结构， 原监事会职权由审计委员会行使，并对《公司章程》进行修订。同时提请股东大 会授权公司董事会办理本次工商变更登记事宜。 表 ...

Core Viewpoint - Haofan Bio (301393) reported that its overseas sales revenue for 2024 is projected to account for 22.13% from Asia, 10.04% from Europe, and 4.09% from America of the total operating revenue [1] Group 1: Company Overview - The main products of the company are specialty chemical raw materials primarily based on peptide synthesis reagents, positioned upstream in the pharmaceutical industry chain [1] - The company offers a wide range of products and serves thousands of customers annually, demonstrating strong risk resistance capabilities [1] Group 2: Market Expansion - The company established a wholly-owned subsidiary in Germany in January 2025, targeting CDMO and formulation clients in the European market to further expand its business in Europe [1]

Core Viewpoint - Haofan Bio's Anhui Phase II project is set to begin trial production in February 2024 and is expected to commence formal production in January 2025, indicating a significant expansion in capacity [2] Group 1: Production Timeline - The Anhui Phase II project will start trial production in February 2024 and formal production in January 2025 [2] - After trial production, the production capacity is expected to stabilize in the first and second quarters of 2025 [2] Group 2: Capacity and Revenue Insights - The relationship between revenue changes and self-owned capacity is not strictly linear, as it is influenced by various factors including product price changes, outsourcing capacity, delivery arrangements, and logistics time [2] - The company is currently experiencing relatively tight capacity and is actively advancing the construction of the Huai'an Haofan production base [2]

（文章来源：证券日报） 证券日报网讯昊帆生物11月18日在互动平台回答投资者提问时表示，公司服务众多医药研发与生产企 业，为下游客户提供以多肽合成试剂和分子砌块为主的各类特色化学试剂。 ...

Core Insights - The peptide synthesis reagent industry is experiencing rapid growth driven by the expanding global peptide drug market, which is projected to reach $110.7 billion in 2024 and $121.7 billion in 2025, with the U.S. holding a dominant share and China showing significant potential [1][6][8] - China's peptide drug market is expected to grow from approximately 55.44 billion yuan in 2024 to 61.2 billion yuan in 2025, providing a solid demand foundation for upstream reagent industries [1][8] - The Chinese peptide synthesis reagent market is projected to grow from about 2.44 billion yuan in 2024 to 2.68 billion yuan in 2025, with strong growth in the ion-type condensation reagent segment [1][9] Industry Overview - Peptide synthesis reagents are specialized chemical agents that facilitate the formation of peptide bonds between amino acids, protect active groups, and suppress side reactions, making them essential in peptide drug development and biomedical research [2][3] - The industry is transitioning from traditional fermentation and extraction methods to chemical synthesis and gene recombination methods, which now dominate the market [5][6] Market Dynamics - The global peptide drug market is expanding due to advancements in synthesis and modification technologies, with a notable increase in demand for innovative therapies targeting chronic diseases [6][8] - In China, the rapid development of the peptide drug market is supported by policy initiatives, clinical demand, and technological advancements, with a projected market size of approximately 554.4 billion yuan in 2024 [8][9] Competitive Landscape - The Chinese peptide synthesis reagent industry features a fragmented competitive landscape with a mix of specialized and comprehensive companies, where most focus on specific types of reagents [10][11] - Leading companies like Haofan Bio are establishing a strong position by offering a full range of peptide synthesis reagents, while other firms focus on niche markets [11][12] Development Trends - The industry is moving towards technological innovation, with a focus on green and efficient synthesis methods, and a shift from single-function to multifunctional reagents [12][13] - Domestic companies are increasingly penetrating high-end markets, breaking the monopoly of international brands in high-purity and low racemization reagents [13][14] - The competitive landscape is evolving from fragmented product competition to an ecosystem of collaborative competition, with leading firms building comprehensive product matrices and enhancing vertical integration [14]

Group 1 - The company, Haofan Bio, announced a cash dividend distribution plan for the first half of 2025, proposing a payout of 1.35 RMB per 10 shares to all shareholders, inclusive of tax [2] - The record date for the dividend distribution is set for November 10, 2025, while the ex-dividend date is November 11, 2025 [2]

特别提示： 1、苏州昊帆生物股份有限公司（以下简称"公司"）回购专用证券账户中的 股份不参与本次权益分派。本次权益分派将以公司现有总股本 108,000,000 股剔 除回购专户股份818,148股后的107,181,852股为基数，向全体股东每10股派1.35 元人民币（含税），公司本次现金分红的总金额=107,181,852 股×1.35 元/10 股 =14,469,550.02 元（含税），本次不送红股，不进行资本公积金转增股本。 2、按公司总股本（含回购股份）折算的每 10 股现金分红（含税）=现金分 红总额÷总股本=14,469,550.02 元÷108,000,000 股×10=1.339773 元（保留六位 小数，最后一位直接截取，不四舍五入），即按公司总股本（含回购股份）折算 的每股现金分红（含税）为 0.1339773 元/股。本次权益分派实施后除权除息参考 价=除权除息日前一交易日收盘价 - 0.1339773 元/股。 证券代码：301393 证券简称：昊帆生物 公告编号：2025-054 苏州昊帆生物股份有限公司 2025 年中期权益分派实施公告 本公司及董事会全体成员保证信息披露内 ...

Core Viewpoint - Haofan Bio, a leading company in the peptide synthesis reagent sector, was established in December 2003 and went public on July 12, 2023, in Shenzhen, with its headquarters in Suzhou, Jiangsu Province [1] Group 1: Business Overview - Haofan Bio specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks, with a focus on peptide drugs, innovative drugs, and biopharmaceuticals [1] - The company has a differentiated advantage in technology and customer resources [1] Group 2: Financial Performance - In Q3 2025, Haofan Bio reported revenue of 435 million yuan, ranking 24th among 34 companies in the industry, while the industry leader, Changchun High-tech, had revenue of 9.807 billion yuan [2] - The net profit for the same period was approximately 99.24 million yuan, placing the company 16th in the industry, with the top performer, Tonghua Dongbao, reporting a net profit of 1.188 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Haofan Bio's debt-to-asset ratio was 7.86%, significantly lower than the industry average of 26.88%, indicating strong solvency [3] - The company's gross profit margin was 38.75%, which is below the industry average of 70.17%, suggesting room for improvement in profitability [3] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.14% to 10,000, while the average number of circulating A-shares held per shareholder increased by 19.09% to 4,200.4 [5] - The fifth largest circulating shareholder, Huatai-PB Health Mixed Fund, increased its holdings by 26,430 shares [5] Group 5: Future Outlook - The company is expected to maintain steady growth, with projected net profits of 166 million, 208 million, and 268 million yuan for 2025 to 2027, respectively, and corresponding EPS of 1.54, 1.93, and 2.48 yuan [5] - Haofan Bio has established a presence in over 1,900 pharmaceutical-related enterprises globally and is actively expanding into the European market [5] - The company is enhancing its production capacity through self-built facilities and acquisitions, with ongoing projects in Anhui and Huai'an expected to resolve capacity issues by mid-2026 [5]

Core Insights - Haofan Bio (301393.SZ) reported its Q3 2025 results, revealing that as of October 28, 2025, six institutional investors held a total of 8.0947 million shares, representing 7.50% of the company's total equity. This marks a decrease of 2.00 percentage points from the previous quarter [1] Institutional Holdings - The institutional investors include Ningbo Haoxin Enterprise Management Consulting Partnership, Suzhou Haoyin Venture Capital Partnership, Industrial and Commercial Bank of China - Huatai Securities Healthcare Mixed Fund, Suzhou Haofan Bio's repurchase special securities account, Abu Dhabi Investment Authority, and Minsheng Securities - CITIC Bank - Minsheng Securities Haofan Bio Strategic Placement No. 1 Collective Asset Management Plan [1] - The public fund that increased its holdings this period is Huatai Securities Healthcare Mixed Fund, with an increase of 0.24% [1] - A total of 75 public funds that were not disclosed in the previous quarter include various funds such as Huisheng Healthcare 6-Month Holding Mixed Fund and others [1] Social Security Fund - One social security fund, the National Social Security Fund 109 Portfolio, was not disclosed in the previous quarter [1]

Core Viewpoint - Haofan Bio (301393.SZ) reported a significant increase in revenue and a modest rise in net profit for the first three quarters of 2025, indicating positive growth trends in its financial performance [1] Financial Performance - The company's operating revenue for the first three quarters reached 435 million yuan, representing a year-on-year growth of 32.47% [1] - The net profit attributable to shareholders of the listed company was 99.24 million yuan, showing a year-on-year increase of 3.01% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 81.27 million yuan, reflecting a year-on-year decrease of 2.79% [1] - Basic earnings per share stood at 0.93 yuan [1]